tiprankstipranks
Summit Therapeutics (SMMT)
NASDAQ:SMMT
US Market
SMMT
Summit Therapeutics
RESEARCH TOOLSreports
Want to see SMMT full AI Analyst Report?

Summit Therapeutics (SMMT) Income Statement

1,891 Followers

Summit Therapeutics Income Statement

Last quarter (Q1 2026), Summit Therapeutics's total revenue was £0.00, a decrease of ― from the same quarter last year. In Q1, Summit Therapeutics's net income was £-189.42M. See Summit Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
£ 0.00£ 0.00£ 0.00£ 704.29K£ 1.81M
Gross Profit
£ 0.00£ -15.01M£ -2.05M£ -1.81M£ 1.81M
Operating Expenses
£ 1.09B£ 226.00M£ 87.69M£ 77.49M£ 88.00M
Depreciation and Amortization
£ 146.00K£ 17.15M£ 155.32K£ 1.26M£ 2.46M
EBITDA
£ -1.08B£ -212.85M£ -69.45M£ -73.12M£ -85.91M
Operating Income
£ -1.09B£ -211.30M£ -89.74M£ -79.30M£ -86.19M
Other Income/Expenses
£ 14.84M£ 4.70M£ -526.14M£ -4.00M£ -2.42M
Pretax Income
£ -1.08B£ -221.31M£ -615.87M£ -83.31M£ -88.60M
Net Income
£ -1.08B£ -221.31M£ -614.93M£ -78.78M£ -88.60M
Per Share Metrics
Basic EPS
£ -1.44£ -0.31£ -0.99£ -0.41£ -0.96
Diluted EPS
£ -1.44£ -0.31£ -0.99£ -0.41£ -0.96
Weighted Average Shares Outstanding
 747.70M 718.54M 619.65M 193.34M 92.24M
Weighted Average Shares Outstanding (Diluted)
 747.70M 718.54M 619.65M 193.34M 92.24M
Currency in GBP

Summit Therapeutics Earnings and Revenue History